Biogen, Neurimmune announce Option Exercise for Aducanumab
02 May 2018 | News
Transaction an increase profit potential of aducanumab for Biogen and provides near-term capital to Neurimmune
Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease.
Biogen will make a one-time $50 million payment to Neurimmune in exchange for a 5% reduction in the original royalty rates on potential commercial sales of aducanumab, which follows the 15% reduction in royalty rates announced in October 2017. The reduced royalty rates on potential commercial sales of aducanumab will be in the high single digits to low-teens.
Biogen licensed the worldwide rights to aducanumab from Neurimmune in 2007.
